Q1 sales, marginally ahead of street estimates, were impacted by the declining demand for COVID-19 testing, as expected. However, excluding COVID-19, both Pharmaceuticals and Diagnostics performed well and 2023 guidance remained unchanged. Overall, we expect the recent sentiment revival for Roche’s shares to extend further and our strong upside is backed by its dominance in most target markets, healthy pipeline execution ability and a robust balance sheet. Important late-stage readouts during th ....

26 Apr 2023
Good start to the year, strong upside reflects intact virtues

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Good start to the year, strong upside reflects intact virtues
- Published:
26 Apr 2023 -
Author:
Abhishek Raval -
Pages:
5 -
Q1 sales, marginally ahead of street estimates, were impacted by the declining demand for COVID-19 testing, as expected. However, excluding COVID-19, both Pharmaceuticals and Diagnostics performed well and 2023 guidance remained unchanged. Overall, we expect the recent sentiment revival for Roche’s shares to extend further and our strong upside is backed by its dominance in most target markets, healthy pipeline execution ability and a robust balance sheet. Important late-stage readouts during th ....